As these compounds go into clinical trials for GC-derived B cell lymphoma (BCL; Wu et al., 2021), it is important to define the normal function of PRMT1 in GCBC, to understand their mechanism of action. Here, PRMT1 is linked to B-cell non-Hodgkin lymphoma.